Blog - Advanced Medicine In China

5 months ago

How Effective is CAR-T Kymriah (Tisagenlecleucel) in Treating Relapsed or Refractory Follicular Lymphoma

How Effective is CAR-T Kymriah (Tisagenlecleucel) in Treating Relapsed or Refractory Follicular Lymphoma Kymriah (Tisagenlecleucel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell...

5 months ago

CAR-T for Lymphoma: The 100th Patient Discharged from Ruijin Hospital in Shanghai

CAR-T for Lymphoma: The 100th Patient Discharged from Ruijin Hospital in Shanghai On March 18, 2024, at Ruijin Hospital in Shanghai, China, the 100th patient with relapsed/refractory lymphoma achie...

5 months ago

A Successful Case of CAR-T Cell Lymphoma Treatment in China

A Successful Case of CAR-T Cell Lymphoma Treatment in China Promising News from Cellular Therapy. On March 29, 2024, Ms. Mo (alias), a patient with diffuse large B-cell lymphoma who received CAR-T ...

5 months ago

International Standards for Innovative Medical Services: The Initial Experience of Singaporean Patients at Jiahui International Hospital

Title: International Standards for Innovative Medical Services: The Initial Experience of Singaporean Patients at Jiahui International Hospital https://www.medtourcn.com/wp-content/uploads/...

5 months ago

创新医疗服务的国际标准：新加坡患者在嘉会医院的初体验

创新医疗服务的国际标准：新加坡患者在嘉会医院的初体验 https://www.medtourcn.com/wp-content/uploads/2024/05/社媒发布节点：上海嘉会新加坡患者-首次就诊印象总结所接受协助.mp4 新加坡患者Teresa女士近期在...

5 months ago

The Hope of CAR-T Cell DLBCL Cure

The Hope of CAR-T Cell DLBCL Cure A Case of CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Can a single injection eliminate cancer cells? If it weren’t for her own p...

5 months ago

Breyanzi Manufacturer is Bristol Myers Squibb (BMS)

Breyanzi Manufacturer is Bristol Myers Squibb (BMS) Breyanzi is developed and produced by the global biopharmaceutical company manufacturer is Bristol Myers Squibb (BMS). Tracing the history of th...

5 months ago

BMS Lisocabtagene Maraleucel (Breyanzi) FDA Approval Date and History

BMS Lisocabtagene Maraleucel (Breyanzi) FDA Approval Date and History Introduction to Breyanzi Breyanzi (lisocabtagene maraleucel; liso-cel) is a CD19-targeted CAR-T cell therapy with a 4-1BB costi...

5 months ago

Breyanzi CAR-T Therapy Receives FDA Accelerated Approval for Expanded Indication in Adult Patients with Relapsed or Refractory Follicular Lymphoma (FL)

Breyanzi CAR-T Therapy Receives FDA Accelerated Approval for Expanded Indication in Adult Patients with Relapsed or Refractory Follicular Lymphoma (FL) Expanded Indication for Breyanzi On May 15th,...

5 months ago

Brexucabtagene Achieves High Central Nervous System Remission Rates in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with Active Central Nervous System Involvement

Brexucabtagene Achieves High Central Nervous System Remission Rates in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with Active Central Nervous System Involvement According to a retrospe...

5 months ago

2024 AACR Meeting: Dynamic Changes in the Tumor Microenvironment from Initial Diagnosis to Sequential Treatment in Patients with Large B-Cell Lymphoma Receiving Axi-cel (Axicabtagene Ciloleucel)

2024 AACR Meeting: Dynamic Changes in the Tumor Microenvironment from Initial Diagnosis to Sequential Treatment in Patients with Large B-Cell Lymphoma Receiving Axi-cel (Axicabtagene Ciloleucel) 20...

5 months ago

Haematologica: The Best Response Rate of CD19 CAR-T Cell Treatment for Lymphoma was 77%

Haematologica: The Best Response Rate of CD19 CAR-T Cell Treatment for Lymphoma was 77% CD19 CAR-T Cell Therapy in Different Subtypes of Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) CD19 CA...

Menu

Our Blog